1059 PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY OF NITAZOXANIDE WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN NONRESPONDERS (NR) WITH CHRONIC HCV GENOTYPE 1: WEEK 28 INTERIM ANALYSIS | Publicación